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Abstract: Background: Since recent observations demonstrated that extended resistance to protease inhibitors, 
nucleosidic and non - nucleosidic retrotranscriptase inhibitors (PI, NRTI, NNRTI) is a marker of disease progression and 
death, it is a matter of the greatest importance that experienced human immunodeficiency virus (HIV) - infected patients 
with limited therapeutic options receive a suppressive therapy pending the availability of at least two new antiretroviral 
drugs. Aim of the present study is to evaluate if the GSS score, calculated by analyzing the resistance to historical 
antiretroviral drugs and drug classes, is still relevant since several new potent drugs and drug classes entered the current 
clinical use. 
Methods: Taking into account patients without suppression of HIV replication for > 6 months from October 2008 and 
October 2009, we analyzed viroimmunological and resistance data of 38 outpatients starting their last antiretroviral 
regimen including at least one of the following: maraviroc, enfuvirtide, raltegravir, etravirine, darunavir/ritonavir or 
tipranavir/ritonavir. Mutations present in all available genotypic resistance tests were recorded for each patient and then 
correlated to GSS value, assessed using the last genotypic ribonucleic acid (RNA) resistance test. GSS was studied as 
predictor of virological treatment outcome by univariate and multivariate logistic regression. 
Results: At 48 weeks, undetectable viral load was obtained in 80% of patients without difference between GSS classes 
(HIV-RNA median <50copies/ml); 95.8% of patients with baseline HIV-RNA <50,000copies/ml obtained virological 
suppression (p=0.003). 48 weeks CD4+ median value was 412 cells/?l considering GSS1 and 300 cells/?l for combined 
GSS2 and GSS3 scores. Data also showed a > 60% recurrence of specific mutations for NRTI: M41L, M184IV, L210W, 
T215FY, K219EQ and 75% for D67N. K103N and Y181CIV mutations for NNRTI persisted in 35% of cases and their 
prevalence incresed in parallel with the number of GRTs. About 60% of tests reported L10FIRVC, M36ILV, M46IL, 
I54VLAMTS, V82AFTSLI, and L90M mutations in the protease region. 63P mutation was found in a total number of 
GRTs close to 80%. This percentages, when correlated to GSS, revealed a distinct pattern for most mutations, that showed 
a greater prevalence for GSS = 2. Conversely, only NNRTI 181CIV and NRTI 210W showed larger numbers in GSS1 and 
GSS3. 
Conclusions: Single drugs belonging to new antiretroviral classes did not correlate to viroimmunological success for any 
GSS. High frequency and recurrence over GRTs for specific mutations confirms their key role following the exposure to 
ARVs classes. A baseline HIV-RNA <50,000 cp/ml is a predictor of therapeutic success and a carefully selected HAART 
based upon the evaluation of GRTs can favorably influence the immunovirologic response. 
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INTRODUCTION 
 Persistent HIV replication in the setting of drug exposure 
can lead to the appearance of amino acid substitutions that 
confers resistance to the current antiretroviral (ARV) 
regimen. 
 Genotype resistance tests (GRTs) have become the 
standard of care and are always recommended to guide 
future regimens following treatment failure [1]. They are  
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based on nucleic acid sequencing of the viral reverse-
transcriptase and protease genes, and now integrase, and 
identification of mutations associated with resistance to 
antiretroviral drugs [1]. 
 Naïve patients represent the “golden standard” for 
applying GRTs [2], and with a high predictive value 
usefulness, due to low prevalence of archived mutations [3-
6]. In patients undergoing multiple virological failures, 
mutation patterns might continuously change and this 
variability can potentially complicate the interpretation of the 
genotypic profile. New resistance mutations are constantly 
developing in patients maintained on virologically 
ineffective antiretroviral regimens [4]. 
 Consequently, in patients with multiple failures, the 
extent of drug resistance detected with the last GRT might be 
underestimated, as several mutations associated with 
previous treatments might not be detected [5]. In case of 
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extended resistance to ?1 drug classes, neglecting archived 
mutations (which were not found at the last GRT, but in 
previous ones) might lead to a rapid failure and even to 
disease progression [6]. 
 Clinical guidelines now recommend GRT in patients with 
antiretroviral treatment failure, in drug- naïve patients and in 
recently infected patients who might have acquired HIV with 
a drug-resistant virus. The cost of GRT guided therapy, 
however, is substantial [7-10] and has prompted a debate 
about the appropriate use and financing of antiretroviral 
resistance testing in Europe and the USA. Its cost-
effectiveness has been documented in a few countries [8]. 
 Some authors [9, 11] found that GRT increases projected 
life-expectancy and quality-adjusted life-expectancy by 2 
and 6 weeks, respectively. This increase in quality-adjusted 
survival is clinically meaningful and comparable to the 
benefit of elective surgery in patients with symptomatic 
gallstones (gain in life-expectancy 1.7 months) [
12
]. 
 Identification of acquired drug resistance mutations is 
critical to achieve virologic suppression and improve 
outcome in patients undergoing multiple virological failures, 
who present complex mutation profiles [13]. 
 The extent of drug resistance detected can be measured 
by a score defined as genotypic sensitivity score (GSS); it 
has been demonstrated to correlate to efficacy [
12, 13
].
 
Nevertheless, a recent analysis demonstrated that with 
newest and more potent drugs, the extended resistance 
profile lacks its association with clinical progression in HIV 
disease [14]. Physicians caring for subjects with HIV/AIDS 
have yet to understand the key role of GSS in determining 
the success of a new antiretroviral regimen that includes the 
latest generation of drugs or if GSS deserves to be supported 
by additional tools that are built on new antiretrovirals. 
PATIENTS AND METHODS 
Study Patients 
 Between March 2008 and April 2008, we selected 
patients with virological failure starting a new regimen with 
maraviroc, enfuvirtide, raltegravir, etravirine, darunavir/r or 
tipranavir/r, alone or in combination among the HIV-1 
infected patients followed at Infectious Diseases and 
Immunopathology Section, University of Milan, Italy. 
Virological failure was defined by two consecutive HIV-
RNA values > 50 copies/ml (cp/ml). 
 Mutations present in all available genotypic resistance 
tests were recorded for each patient. 
 The last genotypic RNA resistance test performed before 
enrollment was considered to assess the GSS; it was then 
correlated to viroimmunological data at 6 and 12 months 
after the beginning of the new regimen. 
Virologic and Immunologic Assays 
 Genotyping was performed at the Infectious Diseases and 
Immunopathology Laboratory, University of Milan, Italy and 
at the “Luigi Sacco” Hospital Central Laboratory, by use of 
commercial assays based on sequencing of complementary 
DNA (cDNA) derived from plasma HIV RNA: the TruGene 
assay (version 2.0; Visible Genetics, Toronto, Canada). It 
generates a 1.3-kb sequence from the pol region 
encompassing the entire protease gene and the major part of 
the reverse-transcriptase gene by bidirectional automated 
sequencing on the Microgene Clipper (Visible Genetics). 
 Drug-resistance results were used to guide treatment 
decisions of patients. 
 Plasma HIV RNA concentrations were measured by 
means of a branched DNA (bDNA) assay with a detection 
limit of 50 cp/ml. Peripheral blood CD4+ lymphocyte counts 
were performed by use of standard flow cytometry. 
Genotypic Susceptibility Scores (GSSs) 
 Baseline genotypic mutation patterns from each patient 
have been correlated to susceptible drugs in the latest ARV 
regimen, thus obtaining a score (GSS). This GSS was then 
compared to efficacy data, as virologic response. 
 A susceptibility score ranging from 0 to 1 was assigned 
to each drug in the salvage regimen. 
 We chose to translate definitions of “resistance” and 
“susceptible or no evidence of resistance” into susceptibility 
scores of 0 and 1, respectively. Only in cases of molecules 
not fully active, resistance for the three historical drug 
classes was assessed using Rega interpretation system 
(version 8.0.1). The sum of the scores of the individual drugs 
in the salvage regimen provided the GSS. 
 The difference between these GSS values is substantial: 0 
means that no drugs under the current regimen are actually 
active against HIV. Likewise, 1, 2 or more indicate the 
number of active drugs within a regimen. 
Statistical Analysis 
 The statistical program used for analyses was ANOVA 
(version 2.0). The differences in the composition of the 
population were considered statistically significant when the 
nonparametric Wilcoxon and Mann - Whitney test for 
continuous variables and the Pearson and Fisher chi - square 
test for categorical variables showed a probability <0.05 
compared to the null hypothesis of equal distributions in the 
groups considered. 
RESULTS 
Patients Baseline Characteristics 
 A total of 38 patients fulfilling the selection criteria was 
included into the study. The median age was 39 years (range, 
26 - 62 years) and 7 individuals (18%) were female. HIV 
risk factors categories were as follows: male homosexuals 
(47%), injection drug users (32%), heterosexuals (20%) and 
unknown (1%). Thirty-eight percent had a previous 
diagnosis of AIDS (Centers for Disease Control and 
Prevention class C criteria [
15
]). 
 The median HIV-RNA level was 13,318 copies/ml 
(range, 369-500,000 copies/ml) and the median CD4+ cell 
count was 234 cells/?l (range, 15-1,197 cells/?l). Before 
enrollment patients had been receiving a potent combination 
regimen for a median of 46 months (range, 18 - 87 months); 
they had had virologic failure with a median of 2 HAART 
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regimens (range 1-7). All patients had been exposed to 3 
antiretroviral drug classes. 
Salvage Treatments 
 Treatments administered after baseline, according to the 
enrollment criterion, included maraviroc, enfuvirtide, 
raltegravir, etravirine, darunavir/r or tipranavir/r, alone or in 
combination. 
 They consisted of 3 antiretroviral drugs in 69% and 4 or 
5 drugs in 31% of patients; darunavir was given to 26 
patients; etravirine to 13; maraviroc to 5; raltegravir to 17; 
tipranavir to 2; enfuvirtide to 9. 
Virological Response 
 After a median follow-up of 48 weeks, 29 patients (76%) 
achieved virologic suppression (VS) defined by HIV-RNA 
<50 copies/ml. VS ranged from 74% to 78% without a 
significant difference when stratified for different GSS (from 
1 to 3). This lack of difference between GSS classes was 
confirmed by a HIV-RNA median value <50cp/ml in any 
GSS class. 
 The 24 weeks CD4+ median was 290/?l for GSS1, 
299/?l for GSS2 and 367/?l for GSS3. This mild increase 
from baseline did not significantly correlate to GSS groups 
(1 versus 2 versus 3 or 1 versus 2 plus 3). After 48 weeks, 
the CD4+ median value was 412/?l for GSS1 and 300/?l for 
combined GSS2 and GSS3 scores. 
 Data analysis showed a > 60% recurrence of specific 
mutations for NRTI: M41L, M184IV, L210W, T215FY, 
K219EQ and 75% for D67N. NNRTI mutations K103N and 
Y181CIV were identified in the 35% of GRTs and their 
prevalence increased in parallel with the number of GRTs. 
About 60% of tests reported L10FIRVC, M36ILV, M46IL, 
I54VLAMTS, V82AFTSLI and L90M mutations in the 
protease region. L63P mutation was found in a total number 
of GRTs close to 80%. 
 As shown in Fig. (1), the prevalence of mutations at 
week 48 varies when considered in relation to GSS. In detail, 
mutations are more frequent in absolute for GSS=2 versus 
GSS=1 and GSS=3. This gap is overall equal to 15% (range 
12% - 17%). 
 Conversely, as shown in Fig. (2), only NNRTI mutation 
Y181CIV and NRTI L210W are less frequent in GSS2 than 
in GSS1 and GSS3 groups. This gap is quite large, being 
equal to 50% (range 49% - 52%). 
 24 weeks data were similar, although with slightly lower 
percentages. 
 Nine patients (24%) underwent virological failure at 48 
weeks. 
 Lastly, the period of observation before the start of the 
study, when all GRTs were performed, amounted to a 
median of 48 months. 
DISCUSSION 
 HIV-1 drug resistance is an important factor responsible 
for failure of antiretroviral treatment. Drug resistance 
emerges and accumulates over time in treated individuals; 
nevertheless several new antiretroviral agents with improved 
activity against resistant viruses have become available 
during more recent years [16]. 
 
 
 
 
 
 
 
Fig. (1). Frequency of mutations related to different GSS values. 
 
 
 
 
 
 
 
Fig. (2). Different frequency of particular mutations related to GSS 
values. 
 Our results at 48 weeks, essentially comparable to 24 
weeks, show that starting an antiretroviral regimen with the 
newest active drugs and drug classes can offer 
viroimmunological success regardless of GSS1, 2 or 3. 
Patient groups were homogenous and lack of statistical 
difference can be easily explained comparing baseline 
viroimmunologic data, characterized by high viral loads and 
low CD4 counts for GSS3 while GSS2 and 1 presented more 
favorable CD4 counts. This finding is consistent with some 
studies [17] although other investigations, conducted in the 
late 1990 decade, support genotypic tests to measure 
regimen potency as independent predictor of viral response 
[18]. 
 Six out of the 9 failed patients referred lack of 
compliance defined as one or more omissions in drug intake 
per week as clearly related to previous multiple virological 
failures. One of them died for P. jiroveci pneumonia due to 
persistently low CD4 cell count. Two patients had 
virological failure probably due to new mutations onset. 
 On the other hand, GSS, mutations and the newest 
antiretrovirals were investigated as predictors of virological 
treatment outcome by univariate and multivariate logistic 
regression. 
 Univariate analyses evidenced lack of correlation 
between specific drugs or mutations and viroimmunological 
outcome, probably for the intrinsic potency of the newer 
antiretrovirals. 
 This might depend on two factors: first, the role of 
archived drug resistance mutations, still not well understood 
[19], although a recent paper underlined a better performance 
of combined current and historical GRTs in identifying 
patients with a complex resistance profile who may benefit 
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from salvage therapies [20]. Undetectable resistances, 
indeed, would weaken the association between GSS and 
treatment responses [21]. 
 Secondly, adherence has been shown to be a major factor 
of virologic failure [10]. This lack of correlation between 
previous drug resistances and virological outcome could 
explain the overlap of the results for different values of GSS. 
 The association emerged between GSS 2 and higher 
frequency of mutations could be explained by a better 
compliance of this category of patients. A great deal of 
adherence would cause a wider and longer drug pressure by 
which viral strains are forced to maintain key mutations. 
This furtherly confirms the key role of mutations following 
the exposure to certain ARVs. 
 According to the literature, we should stress that the 
finding of a median baseline HIV-RNA <50,000 cp/ml is 
more likely associated to virological success. 
 It was not possible to carry out multivariate analysis due 
to small number of patients, which is a major limitation of 
our study. Preliminary assessment on the power of the study 
ruled that a sufficient number of patients would have been 
equal to 80. Failed patients in our Clinic were not so many 
and multicenter study could not have been possible, 
worth the change in the methods. 
 Our results evidence that a carefully selected HAART 
based upon the evaluation of GRTs can favorably influence 
the immunovirologic response at 24 and most significantly at 
48 weeks. 
 Only a longer period of observation will confirm the 
durability of the new ARV regimens in relation to GSS 1, 2 
or 3. Nevertheless these data should be confirmed in larger 
cohorts. 
SUMMARY 
 The frequency and the recurrence across genotypic 
resistance tests (GRTs) of the major mutations correlate to 
genotypic sensitivity score value (GSS); therefore, a 
HAART selected on the basis of a careful evaluation of 
GRTs can favorably influence the 48 weeks 
immunovirologic response. 
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